J&J Seeks Expanded Use of Lung Cancer Drug Rybrevant

The sBLA seeks Rybrevant's approval in combination with chemotherapy (carboplatin and pemetrexed) for the treatment of patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) for patients whose disease has progressed on or after treatment with AstraZeneca’s Tagrisso (osimertinib).